Synovial Tissue Histology for B Cell Targeted Therapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining susceptibility to B cell targeted therapies, such as Rituximab, in rheumatoid arthritis patients are inadequate, as they rely on peripheral blood biomarkers, and there is a need for alternative treatments for patients refractory to Rituximab due to its limited efficacy and safety concerns.
Innovation Solution
Analyzing B cell levels and morphology in synovial tissue samples using histological analysis to predict patient response to B cell targeted therapies, with B cell rich and GC-LS negative samples indicating susceptibility and B cell poor and GC-LS positive samples indicating resistance, allowing for tailored treatment approaches, including the use of Rituximab or agents that downregulate IL-6 signaling like Tocilizumab.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If peripheral blood biomarkers are used to determine susceptibility to B cell targeted therapies, then the assessment is non-invasive and easy to perform, but the prediction accuracy is insufficient
Solution Approach 1:
The invention transitions from assessing B cell levels in peripheral blood (one dimension) to analyzing synovial tissue histology (another dimension). This dimensional shift from blood to tissue provides more accurate prediction of treatment response while maintaining clinical feasibility through image analysis of synovial biopsies
2Reliability
If Rituximab is used to treat RA patients refractory to anti-TNF therapy, then B cell depletion is achieved, but not all patients respond and safety concerns arise
Solution Approach 1:
The invention performs preliminary assessment of synovial tissue histology before initiating Rituximab treatment. By evaluating B cell density and germinal centre-like structure presence in advance, clinicians can predict which patients are likely to respond, thereby avoiding unnecessary treatment and its associated risks for non-responders
Solution Approach 2:
The invention establishes a feedback mechanism where synovial tissue analysis results guide treatment decisions. The histological assessment provides information that feeds back into the treatment selection process, allowing clinicians to choose Rituximab only for patients with favorable histological features (B cell rich, GC-LS negative)
3Productivity
If B cell targeted therapy is administered without histological assessment, then treatment can be started quickly, but treatment failure occurs in patients with GC-LS positive synovium
Solution Approach 1:
The invention performs a relatively quick synovial tissue assessment (taking 1-2 hours with image analysis) before treatment initiation. This preliminary histological evaluation provides rapid prediction of treatment response, enabling faster decision-making compared to lengthy monitoring of treatment failure
Solution Approach 2:
The invention introduces synovial tissue histology analysis as an intermediary between treatment decision and treatment initiation. This intermediary assessment provides critical information about B cell presence and GC-LS structures, mediating the selection of appropriate therapy while maintaining relatively quick treatment initiation
Data Source
AI summary
The present invention provides a method for determining whether a Rheumatoid Arthritis (RA) patient is susceptible to treatment with a B cell targeted therapy, which method comprises the step of analysing B cells and/or germinal centre-like structures (GC-LS) in a synovial tissue sample from the patient; wherein a patient whose synovial tissue sample is B cell rich and/or GC-LS negative is determined to be susceptible to treatment with the B cell targeted therapy, whereas a patient whose synovial tissue sample is B-cell poor and/or GC-LS positive is determined to be resistant to treatment with the B cell targeted therapy.